Intra-Cellular Therapies (ITCI) Tops Q4 Loss Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Intra-Cellular Therapies (ITCI) Tops Q4 Loss Expectations
February 25, 2016 7:02 AM EST
NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2015, and provided a corporate update.
Selected Fourth Quarter and Year End 2015 Financial Results                                                                                                                          Intra-Cellular Therapies (the Company) reported a net loss of $28.8 million, or $0.67 per share (basic and diluted), for the fourth quarter of 2015 compared to a net loss of $15.2 million, or $0.52 per share (basic and diluted), for the fourth quarter of 2014. The Company reported a net loss of $104.8 million, or $2.91 per share (basic and... More
